COMMUNIQUÉS West-GlobeNewswire

Valneva Initiates Second Phase 2 Study for its Lyme Disease Vaccine Candidate VLA15
01/07/2019
Valneva Initiates Second Phase 2 Study for its Lyme Disease Vaccine Candidate VLA15 Saint-Herblain (France), July 1, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing [...]
Valneva initie la deuxième étude de Phase 2 pour son candidat vaccin contre la maladie de Lyme VLA15
01/07/2019
Valneva initie la deuxième étude de Phase 2 pour son candidat vaccin contre la maladie de Lyme VLA15 Saint-Herblain (France), 1 juillet 2019 – Valneva SE (“Valneva” ou “le Groupe”), société de biotechnologie développant [...]
Nicox: Number of voting rights as of June 30, 2019
01/07/2019
Nicox SA Société anonyme with a registered capital of € 29,910,120 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On July 1, 2019, MONTHLY PUBLICATION OF THE [...]
Nicox : Nombre de droits de vote au 30 juin 2019
01/07/2019
Nicox SA Société anonyme au capital de 29 910 120 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 1 er juillet 2019, PUBLICATION MENSUELLE DU NOMBRE D’ [...]
Spineway : Defer of the the General Shareholders’ Meeting of June 208 2019
01/07/2019
Defer of the the General Shareholders’ Meeting of June 208 2019 The Ordinary and Extraordinary General Shareholders' Meeting of Spineway, convened on June 28 2019 at 14H00 CET at the Company's registered office, has not [...]
SPINEWAY : Report de l’Assemblée Générale du 28 juin 2019
01/07/2019
Report de l’Assemblée Générale du 28 juin 2019 L'Assemblée Générale Ordinaire et Extraordinaire des actionnaires de Spineway, convoquée le 28 juin 2019 à 14 heures au siège social de la Société, n’a pas atteint le [...]
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
01/07/2019
Basel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both signs and symptoms [...]
Declaration of the number of shares and voting rights 06/2019
01/07/2019
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Déclaration d'actions et de droits de vote 06/2019
01/07/2019
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Asklepion Pharmaceuticals concludes enrollment of Phase III trial: L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects
01/07/2019
BALTIMORE, July 01, 2019 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”), a biotechnology company focused on the development of novel therapeutics for rare pediatric diseases, today [...]
Transactions under Novozymes’ stock buyback program
01/07/2019
Please read the full announcement in the attached PDF Attachment 2019_21_Stock_Buybackprogram_EN
ClareMedica Health Partners and Beecken Petty O’Keefe & Company Form Partnership With Equity Investment
01/07/2019
CEO Roberto Palenzuela and Team Poised to Lead a Series of Florida-Based Primary Care Practice Acquisitions MIAMI, July 01, 2019 (GLOBE NEWSWIRE) -- ClareMedica Health Partners, LLC (“ClareMedica”) one of Florida’s [...]
The Joint Corp. Joins Russell 2000® and 3000® Indexes
01/07/2019
SCOTTSDALE, Ariz., July 01, 2019 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, will join the small-cap Russell 2000 ® Index and broad-market [...]
Becker’s Hospital Review Names North American Partners in Anesthesia (NAPA) a Top Place to Work in Healthcare for Fourth Consecutive Year
01/07/2019
MELVILLE, N.Y., July 01, 2019 (GLOBE NEWSWIRE) -- North American Partners in Anesthesia (NAPA), one of the leading single-specialty anesthesia and perioperative management companies in the US, is honored to be [...]
Managers' transactions
01/07/2019
Company Announcement No. 13 / 2019 For further information please contact: Martin Riise, Senior Director, Investor Relations, Tel: +45 5339 2250 Annika Stern, Investor Relations Officer, Tel: +45 2399 2382 Camilla [...]
Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
01/07/2019
Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union Libtayo is the only treatment approved in the EU for adult patients with metastatic or locally advanced cutaneous [...]
Sanofi : Libtayo® (cemiplimab) approuvé dans l’Union européenne pour le traitement du carcinome épidermoïde cutané au stade avancé
01/07/2019
Libtayo® (cemiplimab) approuvé dans l’Union européenne pour le traitement du carcinome épidermoïde cutané au stade avancé Libtayo est le seul médicament approuvé dans l’UE pour le traitement du carcinome épidermoïde [...]
Coherus BioSciences Production Exceeds Four-Hundred Thousand UDENYCA® (pegfilgrastim-cbqv) Pre-Filled Syringes
01/07/2019
REDWOOD CITY, Calif., July 01, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company,” Nasdaq: CHRS), is pleased to announce that it has produced over 400,000 UDENYCA® pre-filled syringes to date [...]
OPKO Health’s BioReference Laboratories Forms a Strategic Collaboration With SOMOS to Improve Health Outcomes of Underserved New Yorkers
01/07/2019
SOMOS, New York City’s Largest Multi-Cultural Physician-Led Network, Selects BioReference as Preferred Provider for Diagnostic Testing BioReference to also assist with Patient-Centered Data Analytics to SOMOS Providers [...]

Pages